Evidence map›Paper›PMID 34272643›Full record

ArticlePharmaceutical research2021

Rational Development of Stable PYY

Christian Poulsen, Marie Østergaard Pedersen, Per-Olof Wahlund, Annika Sjölander, Jens Kaalby Thomsen, Kilian W Conde-Frieboes, Johan F Paulsson, Birgitte S Wulff, Søren Østergaard

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Molecular Design of Unimolecular Tetra-Receptor Agonists.Journal of the American Chemical Society · 2025
    Article
  4. Article
  5. Review
  6. Anti-obesity drug discovery: advances and challenges.Nature reviews. Drug discovery · 2022
    Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Christian PoulsenGlobal Research Technology, Novo Nordisk A/S, Måløv, Denmark. chpo@novonordisk.com.ORCID http://orcid.org/0000-0002-8899-2045
Marie Østergaard PedersenGlobal Research Technology, Novo Nordisk A/S, Måløv, Denmark.
Per-Olof WahlundGlobal Research Technology, Novo Nordisk A/S, Måløv, Denmark.
Annika SjölanderGlobal Research Technology, Novo Nordisk A/S, Måløv, Denmark.
Jens Kaalby Thomsen, Hellerup, Denmark.
Kilian W Conde-FrieboesGlobal Research Technology, Novo Nordisk A/S, Måløv, Denmark.
Johan F PaulssonGlobal Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Birgitte S WulffGlobal Drug Discovery, Novo Nordisk A/S, Måløv, Denmark.
Søren ØstergaardGlobal Research Technology, Novo Nordisk A/S, Måløv, Denmark.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe anorectic effect of PYY

methodsHalf-life extended PYY

resultsDeamidation of asparagine in position 18 and 29 was observed upon incubation at 37°C. Asparagine in position 18 - but not position 29 - could be substituted to glutamine without detrimental effects on Y

conclusionsBy rational design, a chemically and physically stable Y

Indexed as

AsparagineDrug DevelopmentHEK293 CellsHumansPeptide FragmentsPeptide YYReceptors, Neuropeptide YAsparagineneuropeptide Y2 receptorPeptide FragmentsPeptide YYpeptide YY (3-36)Receptors, Neuropeptide Ybiophysicsmolecular designpeptide(s)PYY3–36stability

Identifiers

PMID34272643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.